Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-1.65% $3.57
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 139.29 mill |
EPS: | -0.710 |
P/E: | -5.03 |
Earnings Date: | Mar 28, 2024 |
SharesOutstanding: | 39.02 mill |
Avg Daily Volume: | 0.210 mill |
RATING 2024-03-28 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Neutral | |
Return On Asset: | Buy | |
DE: | Sell | |
P/E: | Strong Buy | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
Ebit | n/a | n/a | n/a | n/a | n/a | |
Asset | n/a | n/a | n/a | |||
Debt | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -5.03 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.86x |
Company: PE -5.03 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.644 (-118.03%) $-4.21 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 3.21 - 3.93 ( +/- 10.06%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.57 (-1.65% ) |
Volume | 0.157 mill |
Avg. Vol. | 0.210 mill |
% of Avg. Vol | 74.97 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.